Development of a cAMP sensor with decreased pH sensitivity. by Katy L. Everett (461878)

Prevalence and anatomic level of stenosis ≥ 50% in either limb. by O. Stivalet (6890189)

Subjects:

Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

Damsin (D) and ambrosin (A) treatment decreases the CSC population. by Wendy Soria Sotillo (4408105)

Decreasing oxygen saturation with corresponding levels of NLR and D-dimer for understanding the interplay of inflammation. by Narendran Gopalan (110148)

Exercise testing criteria to diagnose lower extremity peripheral artery disease assessed by computed-tomography angiography by O. Stivalet (6890189)

Subjects:

Exercise test characteristics for identifying stenosis ≥ 50% in any limb among the 60 limbs with normal ABIs (> 0.91). by O. Stivalet (6890189)

Subjects:

Test characteristics for identifying stenosis ≥ 50% in any limb from aorta till popliteal artery in the overall population (<i>n = 126 limbs</i>). by O. Stivalet (6890189)

Subjects:

Reduced follicles, decreased ovulation and decreased fertilization of female Meox-2-cre/Separase S1121A mutant mice. by Juan Xu (225010)

Decreased oscillatory flow decreases <i>klf2a</i> expression. by Julien Vermot (257990)

“…<p>(A) RFF is decreased by alterations in heart rate. …”

Venn diagram of the distribution of the participants between the lowest quartiles of BMD according to DXA of the femoral neck (n = 42+50 = 92) and DXL of the calcaneus (n = 44+50 =... by Hans Lundin (800973)

Subjects:

NFκB-p50 knockdown decreases CD44 expression. by Shannon M. Smith (115335)

Expression of ApoB-50 decreased lipid accumulation and inhibited HCV production. by Bei Wang (116772)

SDG decreases iron-induced apoptosis in H9c2 cells. by Stephanie Puukila (568109)

Sodium taurocholate decreased higher order oligomerization. by Eunhee Lee (804130)

Subjects:

Vasodilator capacity to decrease maximal hypoxic mPAP and AUC_SaO2. by Eva Maria Becker (451197)

“…<p>Vasodilator capacity to decrease maximal hypoxic mPAP (positive treatment effect) and AUC_SaO2 (unwanted desaturation effect) based on (A) pooled effects at all dose levels tested (N = 6, four doses per group) and (B) at each drug's maximal effective dose (i.e., cumulative dose) (mean ± SEM, N = 6, doses as indicated). …”

DMB treatment decreased neuronal apoptosis in cerebral ischemia. by Huinan Zhang (849524)

Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%. by Joseph Kamgno (81039)

“…<p>Pre-treatment LLM, month of start and end of sustained (≥ 4 months) decrease in LLM by ≥ 50% from pre-treatment LLM, to < 8100 mf/ml or < 30000 mf/ml by treatment arm for participants with a sustained decrease by ≥ 50%.…”

The fraction of predicted heterozygotes that are set to “No Call” by RHA decreases as the size of the heterozygote cluster increases. by Orna Mizrahi-Man (42539)

Stroma decreases spheroid size by decreasing cell width. by Karen F. Chambers (224337)